Gilead Sciences, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 27.30B | 27.28B | 27.12B | 28.75B | 29.44B | 2.4% | |
| Cost of Revenue | (6.60B) | (5.66B) | (6.50B) | (6.25B) | (6.23B) | -0.3% | |
Gross Profit | 20.70B | 21.62B | 20.62B | 22.50B | 23.21B | 3.1% | |
| Operating Expenses | |||||||
| Research & Development | (4.60B) | (4.98B) | (5.72B) | (5.91B) | (5.80B) | -1.8% | |
| Selling, General & Administrative | (5.25B) | (5.67B) | (6.09B) | (6.09B) | (5.71B) | -6.3% | |
| General & Administrative | (4.51B) | (4.89B) | (2.82B) | (2.64B) | (2.19B) | -17.1% | |
| Selling & Marketing | (735.00M) | (778.00M) | (3.27B) | (3.45B) | (3.52B) | 2.0% | |
| Depreciation & Amortization | (2.05B) | (2.10B) | (2.69B) | (2.77B) | (2.76B) | -0.3% | |
Operating Income (EBIT) | 9.92B | 7.33B | 7.61B | 1.66B | 11.70B | 604.0% | |
| Non-Operating Items | |||||||
| Interest Income | — | 106.00M | 376.00M | 281.00M | 349.00M | 24.2% | |
| Interest Expense | (1.00B) | (935.00M) | (944.00M) | (977.00M) | (1.02B) | 4.8% | |
| Other Income/Expenses (Net) | -1.64B | -1.52B | -746.00M | -972.00M | -1.91B | 96.0% | |
Income Before Tax | 8.28B | 5.81B | 6.86B | 690.00M | 9.80B | 1319.7% | |
| Income Tax Expense | (2.08B) | (1.25B) | (1.25B) | (211.00M) | (1.29B) | 509.5% | |
Net Income | 6.22B | 4.59B | 5.67B | 480.00M | 8.51B | 1672.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $5 | $4 | $5 | $0 | $7 | 1700.0% | |
| Weighted Avg Shares Outstanding | 1.26B | 1.25B | 1.25B | 1.25B | 1.24B | -0.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 1.26B | 1.26B | 1.26B | 1.25B | 1.25B | 0.0% | |
EBITDA | 11.33B | 8.85B | 10.50B | 4.43B | 13.58B | 206.3% |
Explore GILD
GILD in the Healthcare
Large Cap